{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:34:07Z","timestamp":1786995247755,"version":"build-2736575974"},"reference-count":70,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis US LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.omta.2025.201661","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T16:44:44Z","timestamp":1766767484000},"page":"201661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Development of a secretable frataxin for enhanced efficacy in treating Friedreich\u2019s Ataxia"],"prefix":"10.1016","volume":"34","author":[{"given":"Daniel M.","family":"DuBreuil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashvi","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikaela","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swathi","family":"Ayloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingeborg M.","family":"Langohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh S.","family":"Bangari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3589-8749","authenticated-orcid":false,"given":"Christian","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam","family":"Ramachandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2025.201661_bib1","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrneurol.2009.26","article-title":"Diagnosis and treatment of Friedreich ataxia: a European perspective","volume":"5","author":"Schulz","year":"2009","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.omta.2025.201661_bib2","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000358801","article-title":"The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies","volume":"42","author":"Ruano","year":"2014","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.omta.2025.201661_bib3","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1080\/03007995.2022.2112870","article-title":"A systematic review of disease prevalence, health-related quality of life, and economic outcomes associated with Friedreich's Ataxia","volume":"38","author":"Buesch","year":"2022","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.omta.2025.201661_bib4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41582-022-00634-9","article-title":"Recessive cerebellar and afferent ataxias - clinical challenges and future directions","volume":"18","author":"Beaudin","year":"2022","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.omta.2025.201661_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00415-009-1002-3","article-title":"Friedreich ataxia: the clinical picture","volume":"256","author":"Pandolfo","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.omta.2025.201661_bib6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00401-011-0844-9","article-title":"The cerebellar component of Friedreich's ataxia","volume":"122","author":"Koeppen","year":"2011","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.omta.2025.201661_bib7","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1007\/s13311-019-00764-x","article-title":"Molecular Mechanisms and Therapeutics for the GAA.TTC Expansion Disease Friedreich Ataxia","volume":"16","author":"Gottesfeld","year":"2019","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.omta.2025.201661_bib8","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/hmg\/6.11.1771","article-title":"Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes","volume":"6","author":"Campuzano","year":"1997","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omta.2025.201661_bib9","doi-asserted-by":"crossref","first-page":"e1499","DOI":"10.1212\/WNL.0000000000200913","article-title":"Natural History of Friedreich Ataxia: Heterogeneity of Neurologic Progression and Consequences for Clinical Trial Design","volume":"99","author":"Rummey","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.omta.2025.201661_bib10","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/acn3.225","article-title":"Frataxin levels in peripheral tissue in Friedreich ataxia","volume":"2","author":"Lazaropoulos","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.omta.2025.201661_bib11","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1136\/jnnp.2003.028605","article-title":"Real time PCR quantification of frataxin mRNA in the peripheral blood leucocytes of Friedreich ataxia patients and carriers","volume":"75","author":"Pianese","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.omta.2025.201661_bib12","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s004150050198","article-title":"Determinants of onset age in Friedreich's ataxia","volume":"245","author":"De Michele","year":"1998","journal-title":"J. Neurol."},{"key":"10.1016\/j.omta.2025.201661_bib13","doi-asserted-by":"crossref","first-page":"41469","DOI":"10.1074\/jbc.M006539200","article-title":"Two-step processing of human frataxin by mitochondrial processing peptidase. Precursor and intermediate forms are cleaved at different rates","volume":"275","author":"Cavadini","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omta.2025.201661_bib14","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/s41467-019-09989-y","article-title":"Structure of the human frataxin-bound iron-sulfur cluster assembly complex provides insight into its activation mechanism","volume":"10","author":"Fox","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2025.201661_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.838335","article-title":"Recent Advances in the Elucidation of Frataxin Biochemical Function Open Novel Perspectives for the Treatment of Friedreich's Ataxia","volume":"16","author":"Monfort","year":"2022","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.omta.2025.201661_bib16","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jns.2011.05.023","article-title":"Mortality in Friedreich ataxia","volume":"307","author":"Tsou","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.omta.2025.201661_bib17","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1089\/hum.2020.264","article-title":"Central Nervous System Therapeutic Targets in Friedreich Ataxia","volume":"31","author":"Harding","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2025.201661_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4330\/wjc.v11.i1.1","article-title":"Heart disease in Friedreich's ataxia","volume":"11","author":"Hanson","year":"2019","journal-title":"World J. Cardiol."},{"key":"10.1016\/j.omta.2025.201661_bib19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.acvd.2021.10.010","article-title":"Characterizing cardiac phenotype in Friedreich's ataxia: The CARFA study","volume":"115","author":"Legrand","year":"2022","journal-title":"Arch. Cardiovasc. Dis."},{"key":"10.1016\/j.omta.2025.201661_bib20","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.tips.2019.02.001","article-title":"Therapeutic Prospects for Friedreich's Ataxia","volume":"40","author":"Zhang","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.omta.2025.201661_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22041815","article-title":"Future Prospects of Gene Therapy for Friedreich's Ataxia","volume":"22","author":"Ocana-Santero","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omta.2025.201661_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21030916","article-title":"The NRF2 Signaling Network Defines Clinical Biomarkers and Therapeutic Opportunity in Friedreich's Ataxia","volume":"21","author":"La Rosa","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omta.2025.201661_bib23","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ana.25934","article-title":"Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study)","volume":"89","author":"Lynch","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omta.2025.201661_bib24","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.29286","article-title":"Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed-Start Analysis of the MOXIe Extension","volume":"38","author":"Lynch","year":"2023","journal-title":"Mov. Disord."},{"key":"10.1016\/j.omta.2025.201661_bib25","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/hmg\/ddr554","article-title":"A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich's ataxia mouse model","volume":"21","author":"Vyas","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omta.2025.201661_bib26","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/jcmm.13365","article-title":"Frataxin-deficient neurons and mice models of Friedreich ataxia are improved by TAT-MTScs-FXN treatment","volume":"22","author":"Britti","year":"2018","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.omta.2025.201661_bib27","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nm.3510","article-title":"Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich's ataxia","volume":"20","author":"Perdomini","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2025.201661_bib28","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/hmg\/ddy427","article-title":"Correction of half the cardiomyocytes fully rescue Friedreich ataxia mitochondrial cardiomyopathy through cell-autonomous mechanisms","volume":"28","author":"Belbellaa","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omta.2025.201661_bib29","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.omtm.2020.08.018","article-title":"High Levels of Frataxin Overexpression Lead to Mitochondrial and Cardiac Toxicity in Mouse Models","volume":"19","author":"Belbellaa","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2025.201661_bib30","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.omtm.2022.02.002","article-title":"In vivo overexpression of frataxin causes toxicity mediated by iron-sulfur cluster deficiency","volume":"24","author":"Huichalaf","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2025.201661_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.819569","article-title":"Cerebellar Pathology in an Inducible Mouse Model of Friedreich Ataxia","volume":"16","author":"Mercado-Ayon","year":"2022","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.omta.2025.201661_bib32","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1089\/hum.2023.020","article-title":"Identification of Safe and Effective Intravenous Dose of AAVrh.10hFXN to Treat the Cardiac Manifestations of Friedreich's Ataxia","volume":"34","author":"Munoz-Zuluaga","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2025.201661_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101193","article-title":"AAV8 gene therapy reverses cardiac pathology and prevents early mortality in a mouse model of Friedreich's ataxia","volume":"32","author":"Chang","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2025.201661_bib34","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1089\/hum.2023.088","article-title":"How Great a Risk Do You Take? A Qualitative Study Exploring Attitudes of Individuals with Friedreich Ataxia Toward Gene Therapy","volume":"34","author":"Lieschke","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2025.201661_bib35","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.ymthe.2018.05.006","article-title":"Rapid and Complete Reversal of Sensory Ataxia by Gene Therapy in a Novel Model of Friedreich Ataxia","volume":"26","author":"Piguet","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2025.201661_bib36","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1016\/j.jmb.2018.05.022","article-title":"High-Throughput Dissection of AAV-Host Interactions: The Fast and the Curious","volume":"430","author":"Herrmann","year":"2018","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.omta.2025.201661_bib37","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1089\/hum.2020.116","article-title":"Quantitative Whole-Body Imaging of I-124-Labeled Adeno-Associated Viral Vector Biodistribution in Nonhuman Primates","volume":"31","author":"Ballon","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2025.201661_bib38","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1089\/hum.2023.060","article-title":"Positron Emission Tomography Quantitative Assessment of Off-Target Whole-Body Biodistribution of I-124-Labeled Adeno-Associated Virus Capsids Administered to Cerebral Spinal Fluid","volume":"34","author":"Rosenberg","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2025.201661_bib39","doi-asserted-by":"crossref","DOI":"10.1172\/JCI185001","article-title":"Cross-species efficacy of AAV-mediated ARSA replacement for Metachromatic Leukodystrophy","volume":"135","author":"Ramachandran","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omta.2025.201661_bib40","unstructured":"Davidson, B.L., Chen, Y., Ranum, P.T., and Liu, X. Adeno-associated viral vector variants US Patent Application US20240100194A filed October 20, 2023, and published March 28, 2024."},{"key":"10.1016\/j.omta.2025.201661_bib41","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/14656566.2024.2343782","article-title":"Pharmacotherapeutic strategies for Friedreich Ataxia: a review of the available data","volume":"25","author":"Gunther","year":"2024","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.omta.2025.201661_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2011.01.010","article-title":"Friedreich's ataxia: pathology, pathogenesis, and molecular genetics","volume":"303","author":"Koeppen","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.omta.2025.201661_bib43","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1073\/pnas.88.8.3431","article-title":"Characterization of tissue-specific transcription by the human synapsin I gene promoter","volume":"88","author":"Thiel","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omta.2025.201661_bib44","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1073\/pnas.90.4.1460","article-title":"Identification of a functional silencer element involved in neuron-specific expression of the synapsin I gene","volume":"90","author":"Li","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omta.2025.201661_bib45","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1074\/jbc.271.6.3317","article-title":"Neuron-specific gene expression of synapsin I. Major role of a negative regulatory mechanism","volume":"271","author":"Schoch","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omta.2025.201661_bib46","first-page":"88","article-title":"Comparative study of the transfection efficiency of commonly used viral vectors in rhesus monkey (Macaca mulatta) brains","volume":"38","author":"Wu","year":"2017","journal-title":"Zool. Res."},{"key":"10.1016\/j.omta.2025.201661_bib47","doi-asserted-by":"crossref","first-page":"6350","DOI":"10.1016\/j.ymthe.2025.08.050","article-title":"Development of an AAV-delivered microRNA gene therapy for Myotonic Dystrophy Type 1","volume":"33","author":"Tomassy","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2025.201661_bib48","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abn4704","article-title":"Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders","volume":"8","author":"El Andari","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omta.2025.201661_bib49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1479-0556-6-13","article-title":"Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice","volume":"6","author":"Pacak","year":"2008","journal-title":"Genet. Vaccines Ther."},{"key":"10.1016\/j.omta.2025.201661_bib50","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ymgme.2003.08.017","article-title":"Targeting proteins to mitochondria using TAT","volume":"80","author":"Del Gaizo","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omta.2025.201661_bib51","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tips.2017.01.003","article-title":"Cell-Penetrating Peptides: From Basic Research to Clinics","volume":"38","author":"Guidotti","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.omta.2025.201661_bib52","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/hmg\/ddy064","article-title":"CDKL5 protein substitution therapy rescues neurological phenotypes of a mouse model of CDKL5 disorder","volume":"27","author":"Trazzi","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omta.2025.201661_bib53","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/mt.2008.256","article-title":"Delivery of therapeutic proteins as secretable TAT fusion products","volume":"17","author":"Flinterman","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2025.201661_bib54","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ng0897-345","article-title":"Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin","volume":"16","author":"Koutnikova","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omta.2025.201661_bib55","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.biocel.2016.10.013","article-title":"Heterologous mitochondrial targeting sequences can deliver functional proteins into mitochondria","volume":"81","author":"Marcus","year":"2016","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.omta.2025.201661_bib56","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ejcb.2018.06.003","article-title":"A comprehensive review of signal peptides: Structure, roles, and applications","volume":"97","author":"Owji","year":"2018","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.omta.2025.201661_bib57","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1093\/bioinformatics\/btx431","article-title":"DeepLoc: prediction of protein subcellular localization using deep learning","volume":"33","author":"Almagro Armenteros","year":"2017","journal-title":"Bioinformatics"},{"key":"10.1016\/j.omta.2025.201661_bib58","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41587-021-01156-3","article-title":"SignalP 6.0 predicts all five types of signal peptides using protein language models","volume":"40","author":"Teufel","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omta.2025.201661_bib59","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/84818","article-title":"Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits","volume":"27","author":"Puccio","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omta.2025.201661_bib60","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1177\/01926233231213851","article-title":"Scientific and Regulatory Policy Committee Technical Review: Biology and Pathology of Ganglia in Animal Species Used for Nonclinical Safety Testing","volume":"51","author":"Bennet","year":"2023","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.omta.2025.201661_bib61","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1089\/hum.2020.167","article-title":"Adeno-Associated Virus-Induced Dorsal Root Ganglion Pathology","volume":"31","author":"Hordeaux","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2025.201661_bib62","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ymthe.2018.01.018","article-title":"The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL\/6J Mice","volume":"26","author":"Hordeaux","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2025.201661_bib63","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.ymthe.2019.07.017","article-title":"AAV-PHP.B Administration Results in a Differential Pattern of CNS Biodistribution in Non-human Primates Compared with Mice","volume":"27","author":"Liguore","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2025.201661_bib64","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.neulet.2017.11.049","article-title":"Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain","volume":"665","author":"Matsuzaki","year":"2018","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.omta.2025.201661_bib65","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41593-021-00969-4","article-title":"AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset","volume":"25","author":"Goertsen","year":"2022","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.omta.2025.201661_bib66","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg6618","article-title":"Primate-conserved carbonic anhydrase IV and murine-restricted LY6C1 enable blood-brain barrier crossing by engineered viral vectors","volume":"9","author":"Shay","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omta.2025.201661_bib68","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1097\/MAO.0000000000000466","article-title":"Efficacy and safety of AM-111 in the treatment of acute sensorineural hearing loss: a double-blind, randomized, placebo-controlled phase II study","volume":"35","author":"Suckfuell","year":"2014","journal-title":"Otol. Neurotol."},{"key":"10.1016\/j.omta.2025.201661_bib69","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.20","article-title":"XG-102 administered to healthy male volunteers as a single intravenous infusion: a randomized, double-blind, placebo-controlled, dose-escalating study","volume":"2","author":"Deloche","year":"2014","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.omta.2025.201661_bib70","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/pme.12058","article-title":"The safety and efficacy of KAI-1678- an inhibitor of epsilon protein kinase C (epsilonPKC)-versus lidocaine and placebo for the treatment of postherpetic neuralgia: a crossover study design","volume":"14","author":"Cousins","year":"2013","journal-title":"Pain Med."},{"key":"10.1016\/j.omta.2025.201661_bib71","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1161\/CIRCULATIONAHA.107.759167","article-title":"Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction","volume":"117","author":"Direct Inhibition of delta-Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction DELTA MI Investigators","year":"2008","journal-title":"Circulation"}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X25000114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X25000114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T21:34:25Z","timestamp":1783028065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X25000114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S3117387X25000114"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2025.201661","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a secretable frataxin for enhanced efficacy in treating Friedreich\u2019s Ataxia","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2025.201661","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sanofi. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201661"}}